BIRC5 and breast carcinoma: We previously also found that paclitaxel-induced survivin expression is through activation of the PI3K-AKT and MEK-ERK1/2 pathways as the paclitaxel-resistant factor, and the inhibition of these two pathways by their specific inhibitors decreased survivin expression and sensitized paclitaxel efficacy in breast cancer cells [20].